SXTC
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B 0.08 suggests assets are vastly undervalued, but operational failure makes these assets illiquid or impaired.
- P/B ratio of 0.08 is nominally 'deep value'
- No P/E or Graham Number available
- Market cap effectively zero
Revenue Growth -24.50% YoY indicates a shrinking business model.
- Revenue growth -24.50%
- Operating margin -1011.69%
Historical price performance is a total wipeout.
- 1Y Change -98.7%
- 5Y Change -100.0%
Ref Piotroski F-Score 5/9; the company is solvent but not profitable.
- Piotroski F-Score 5/9
- Low Debt/Equity
- High Quick Ratio
- Negative ROE/ROA
Yield N/A
- No dividend history
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SXTC and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SXTC
China SXT Pharmaceuticals, Inc.
Primary
|
-100.0% | -99.8% | -98.7% | -99.0% | +47.1% | -11.2% |
|
RDGT
Ridgetech, Inc.
Peer
|
-100.0% | -99.9% | -98.5% | -99.1% | -99.3% | -11.5% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
|
IMCC
IM Cannabis Corp.
Peer
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SXTC
China SXT Pharmaceuticals, Inc.
|
BEARISH | $1.97M | - | -50.3% | -% | $2.06 | |
|
RDGT
Ridgetech, Inc.
|
BEARISH | $2.0M | - | -8.0% | 10.3% | $2.23 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning SXTC from our newsroom.